Seems Like Some Have Given up - Big Mistake!

icellman
Full Member

Posts: 143

Seems Like Some Have Given up - Big Mistake! Dec 6, 2015 20:30:57 GMT goldencoin9999, actranger, and 1 more like this

Quote

Post by icellman on Dec 6, 2015 20:30:57 GMT

The sentiment I've been seeing reading this board and the Icell board is that people are resigned to the fact that there's no hope and we'll see no other offers and that we would have seen a compnay step forward by now if they were interested in acquiring OCAT. This may very well be the case, but think about this for a moment.

If any other Big Pharma would step forward knowing what they know from the non diclosure agreements, it wouldn't have been earlier or even now. They are going to wait until the last second for the simple fact that they wouldn't want to foster a bidding war. They'll want to pick up this technology as quietly and cheaply as possible and get out of dodge. The only way to do that would be to scoop in at the last second. Again, this may be totally off base and may never happen, but I'm hedging my bet and waiting until then to find out. I would never forgive myself to own this stock for 8 years and cash out and be on the outside looking in if this were to happen.

It's been quite a learning experience with this stock over the last 8 years Best of luck to everyone no matter what one decides to do.

Last Edit: Dec 6, 2015 20:35:05 GMT by icellman

goldencoin9999 Full Member Posts: 107	Seems Like Some Have Given up - Big Mistake! Dec 6, 2015 20:48:33 GMT Quote Select Post Deselect Post Link to Post Member Give Gift Back to Top Post by goldencoin9999 on Dec 6, 2015 20:48:33 GMT right on! I am there with you.

selluwud God Posts: 2,064	Seems Like Some Have Given up - Big Mistake! Dec 6, 2015 22:04:25 GMT Quote Select Post Deselect Post Link to Post Member Give Gift Back to Top Post by selluwud on Dec 6, 2015 22:04:25 GMT I'm holding, but I don't expect anything but disappointment for any other chances to sell at any price higher than the 8.50 offer save the daily market fluctuations.

spambox
Full Member

Posts: 105

Seems Like Some Have Given up - Big Mistake! Dec 6, 2015 22:12:55 GMT

Quote

Post by spambox on Dec 6, 2015 22:12:55 GMT

Just a thought: if you want out NOW, at least place a GTC limit order to sell at $8.50 on the market for a few days rather than tender your shares to Astellus. In doing so, those people holding have a chance to buy and hold your shares as well, rather than you giving them straight to Astellus. Plus in many cases you pay more fees to tender than you do selling to market (depending on your broker).

I am holding still, but BP or someone else need to act soon or it will be too late. I wouldn't put it past Wotton to conveniently delay responding to a new tender offer until it was too late, if submitted at the last minute.

BP will not "scoop in at the last second" and try to buy everything up in the hopes that less than 50% of shares have been tendered - they wouldn't take that risk, because doing so would remove an upper limit on what BP would be prepared to pay for Ocata. They will not do what is effectively a hostile takeover. What they will do (if anything) is make a new higher tender offer to Wotton, and that offer has to be sufficiently sweeter for Wotton personally or he won't take it (I think it's clear at this point that Wotton is acting for Wotton first and foremost, not retail shareholders), and these things take time.

Again, sorry, but BP leaving it to "scoop in at the last second" is hugely risky and makes no business sense for them, and just isn't going to happen. They risk losing everything they pay above $8.50 if they don't get >50% of the shares... and actually even that wouldn't matter since they couldn't vote anyway. A bigger tender offer is what BP would do, which puts a precise value on what the BP is prepared to put on the line to take Ocata, and they need to submit it allowing enough time for Wotton to act on it.

Last Edit: Dec 6, 2015 22:21:16 GMT by spambox

Wotton = Judas.

greatceasarsghost
Full Member

Intimate JV coming...the kind of JV that holds you tight and makes sweet sweet love to you.

Posts: 234

Seems Like Some Have Given up - Big Mistake! Dec 7, 2015 0:07:29 GMT runawaykinms likes this

Quote

Post by greatceasarsghost on Dec 7, 2015 0:07:29 GMT

Dec 6, 2015 20:30:57 GMT icellman said:

The sentiment I've been seeing reading this board and the Icell board is that people are resigned to the fact that there's no hope and we'll see no other offers and that we would have seen a compnay step forward by now if they were interested in acquiring OCAT. This may very well be the case, but think about this for a moment.

If any other Big Pharma would step forward knowing what they know from the non diclosure agreements, it wouldn't have been earlier or even now. They are going to wait until the last second for the simple fact that they wouldn't want to foster a bidding war. They'll want to pick up this technology as quietly and cheaply as possible and get out of dodge. The only way to do that would be to scoop in at the last second. Again, this may be totally off base and may never happen, but I'm hedging my bet and waiting until then to find out. I would never forgive myself to own this stock for 8 years and cash out and be on the outside looking in if this were to happen.

It's been quite a learning experience with this stock over the last 8 years Best of luck to everyone no matter what one decides to do.

Pardon my ignorance, but wouldn't swooping in at the last minute basically restart the whole clock?

spambox
Full Member

Posts: 105

Seems Like Some Have Given up - Big Mistake! Dec 8, 2015 13:48:38 GMT

Quote

Post by spambox on Dec 8, 2015 13:48:38 GMT

A higher tender offer (if Wotton accepts it) would restart the clock I believe. I don't know if that means all those who tendered already to Astellus would get their shares back, since the 20 day period is not over yet... interesting.

Last Edit: Dec 8, 2015 13:48:56 GMT by spambox

Wotton = Judas.

jak
Junior Member

Pic reflects current mood

Posts: 88

Seems Like Some Have Given up - Big Mistake! Dec 8, 2015 15:21:20 GMT

Quote

Post by jak on Dec 8, 2015 15:21:20 GMT

Zacks with a target of $9.50 on Dec 8th .... you must wonder if they know something.

www.dakotafinancialnews.com/ocata-therapeutics-inc-ocat-stock-rating-upgraded-by-zacks-investment-research/712848/

Ocata Therapeutics Inc (OCAT) Stock Rating Upgraded by Zacks Investment Research
December 8th, 2015 - 0 comments - Filed Under - by Mark Watkins
Share on StockTwits

Ocata Therapeutics logoOcata Therapeutics Inc (NASDAQ:OCAT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, MarketBeat reports. The brokerage presently has a $9.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 12.16% from the stock’s previous close.

According to Zacks, “Ocata Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata focuses on the development of methods to generate replacement cells from both human embryonic and adult stem cells. The Company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata Therapeutics, Inc., formerly known as named Advanced Cell Technology, is based in United States. “

Several other equities research analysts have also issued reports on the company. Raymond James lowered Ocata Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 10th. Cantor Fitzgerald assumed coverage on Ocata Therapeutics in a report on Friday, October 9th. They set a “buy” rating and a $9.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.83.

Ocata Therapeutics (NASDAQ:OCAT) traded down 0.12% during trading on Monday, hitting $8.47. 821,956 shares of the stock traded hands. The stock’s market cap is $358.28 million. Ocata Therapeutics has a 52-week low of $3.06 and a 52-week high of $8.71. The company’s 50 day moving average price is $6.50 and its 200-day moving average price is $5.26.

Ocata Therapeutics (NASDAQ:OCAT) last released its earnings results on Monday, November 9th. The biotechnology company reported ($0.09) earnings per share for the quarter. Equities research analysts forecast that Ocata Therapeutics will post ($0.62) earnings per share for the current fiscal year.

In other Ocata Therapeutics news, insider Robert Lanza sold 35,000 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $8.31, for a total value of $290,850.00. Following the transaction, the insider now owns 196,509 shares of the company’s stock, valued at $1,632,989.79. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Get a free copy of the Zacks research report on Ocata Therapeutics (OCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

selluwud
God

Posts: 2,064

Seems Like Some Have Given up - Big Mistake! Dec 8, 2015 15:23:53 GMT phoenix200k likes this

Quote

Post by selluwud on Dec 8, 2015 15:23:53 GMT

Dec 8, 2015 15:21:20 GMT jak said:

Zacks with a target of $9.50 on Dec 8th .... you must wonder if they know something.

www.dakotafinancialnews.com/ocata-therapeutics-inc-ocat-stock-rating-upgraded-by-zacks-investment-research/712848/

Ocata Therapeutics Inc (OCAT) Stock Rating Upgraded by Zacks Investment Research
December 8th, 2015 - 0 comments - Filed Under - by Mark Watkins
Share on StockTwits

Ocata Therapeutics logoOcata Therapeutics Inc (NASDAQ:OCAT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, MarketBeat reports. The brokerage presently has a $9.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 12.16% from the stock’s previous close.

According to Zacks, “Ocata Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata focuses on the development of methods to generate replacement cells from both human embryonic and adult stem cells. The Company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata Therapeutics, Inc., formerly known as named Advanced Cell Technology, is based in United States. “

Several other equities research analysts have also issued reports on the company. Raymond James lowered Ocata Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 10th. Cantor Fitzgerald assumed coverage on Ocata Therapeutics in a report on Friday, October 9th. They set a “buy” rating and a $9.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.83.

Ocata Therapeutics (NASDAQ:OCAT) traded down 0.12% during trading on Monday, hitting $8.47. 821,956 shares of the stock traded hands. The stock’s market cap is $358.28 million. Ocata Therapeutics has a 52-week low of $3.06 and a 52-week high of $8.71. The company’s 50 day moving average price is $6.50 and its 200-day moving average price is $5.26.

Ocata Therapeutics (NASDAQ:OCAT) last released its earnings results on Monday, November 9th. The biotechnology company reported ($0.09) earnings per share for the quarter. Equities research analysts forecast that Ocata Therapeutics will post ($0.62) earnings per share for the current fiscal year.

In other Ocata Therapeutics news, insider Robert Lanza sold 35,000 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $8.31, for a total value of $290,850.00. Following the transaction, the insider now owns 196,509 shares of the company’s stock, valued at $1,632,989.79. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Get a free copy of the Zacks research report on Ocata Therapeutics (OCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

They must not know Jack, as they don't even mention Astellas. What a crock, that is a terrible attempt at selling an investment service. It must be automatically generated based on price/market movement.

Last Edit: Dec 8, 2015 15:24:31 GMT by selluwud

greatceasarsghost Full Member Intimate JV coming...the kind of JV that holds you tight and makes sweet sweet love to you. Posts: 234	Seems Like Some Have Given up - Big Mistake! Dec 8, 2015 15:41:18 GMT Quote Select Post Deselect Post Link to Post Member Give Gift Back to Top Post by greatceasarsghost on Dec 8, 2015 15:41:18 GMT ^Looks like people read it and are buying. Sad.

rickrick
Moderator

Posts: 439

Seems Like Some Have Given up - Big Mistake! Dec 8, 2015 22:15:18 GMT phoenix200k likes this

Quote

Post by rickrick on Dec 8, 2015 22:15:18 GMT

What I see is that if the road show couldn't even get 4.50/sh with basically the same knowledge as is known now (maybe slightly different buy not by much) why would big pharma come riding in on it's white horse now to save the science at almost 3 times what they could have paid for it back then but said 'thanks, but no thanks).

If this science was the holy grail of mankind why is Coffey's system still being treated as hopeful, or why is gene therapy staying on the forefront of the radar, or why haven't a dozen other things occurred over the years that were supposed to occur.

Everything about this company from the beginning of it's existence has only been promises and non truths.

For every real concrete evidence they have claimed there has been a dozen non concrete promises.

Make a list of things real and things promised/have not come true and see how it looks on paper. This will show where the company really is in the world, not what we hoped or thought it was going to be, it's no where near what we thought it would be by now.

Big pharma can see and will direct which way the bio/drug industry will go and that's why they snatch up these small bio techs. Regen has a future but it's not now and when it does come it will be how big pharma want's it to be which will be in a way they can make the billions they will be losing from drugs going away.

This is just Astellas snatching up the opportunity to play when the time comes.

The fool thinks himself to be wise, but the wise man knows himself to be a fool.

Seems Like Some Have Given up - Big Mistake!

Post by icellman on Dec 6, 2015 20:30:57 GMT

Post by goldencoin9999 on Dec 6, 2015 20:48:33 GMT

Post by selluwud on Dec 6, 2015 22:04:25 GMT

Post by spambox on Dec 6, 2015 22:12:55 GMT

Post by greatceasarsghost on Dec 7, 2015 0:07:29 GMT

Post by spambox on Dec 8, 2015 13:48:38 GMT

Post by jak on Dec 8, 2015 15:21:20 GMT

Post by selluwud on Dec 8, 2015 15:23:53 GMT

Post by greatceasarsghost on Dec 8, 2015 15:41:18 GMT

Post by rickrick on Dec 8, 2015 22:15:18 GMT